Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer

This study has been completed.
Sponsor:
Collaborators:
Eli Lilly and Company
Genentech, Inc.
Information provided by:
SCRI Development Innovations, LLC
ClinicalTrials.gov Identifier:
NCT00193076
First received: September 12, 2005
Last updated: May 2, 2011
Last verified: May 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2008
  Primary Completion Date: May 2006 (Final data collection date for primary outcome measure)
Publications: